October 4, 2024Open Access

An Ultra-Fast Green UHPLC-MS/MS Method for Assessing the in Vitro Metabolic Stability of Dovitinib: In Silico Study for Absorption, Distribution, Metabolism, Excretion, Metabolic Lability, and DEREK Alerts

MAMohamed W. AttwaKing Saud University AAAli S. AbdelhameedUniversity of Nottingham AKAdnan A. KadiKing Saud University

Key Points

Key points are not available for this paper at this time.

Abstract

: Dovitinib (DVB) is a pan-tyrosine kinase inhibitor (TKI) that can be administered orally. In September 2023, the FDA granted Oncoheroes approval to proceed with an Investigational New Drug (IND) application for dovitinib. This application is intended for the treatment of relapsed or advanced juvenile solid tumors, namely, osteosarcoma.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Attwa et al. (Fri,) studied this question.

synapsesocial.com/papers/68e55c81e2b3180350ef9f83 https://doi.org/https://doi.org/10.3390/medicina60101626